NCT02467452View on ClinicalTrials.gov

Non Inferiority of Fixed Combination of Beclomethasone Dipropionate (BDP) + Formoterol Fumarate (FF) + Glycopyrronium Bromide (GB) Versus Combination of Fluticasone Furoate (FlF)/Vilanterol (VI) + Tiotropium Bromide in Chronic Obstructive Pulmonary Disease (COPD)

PHASE3CompletedINTERVENTIONAL

Enrollment

1,479

Participants

Timeline

Start Date

May 31, 2015

Primary Completion Date

January 31, 2017

Study Completion Date

January 31, 2017

Conditions

Chronic Obstructive Pulmonary Disease

Interventions

DRUG

BDP/FF/GB

DRUG

FlF/VI + Tiotropium

Trial Locations (1)

2100

Erzsebet Gondozohaz, Gödöllő

All Listed Sponsors

lead

Chiesi Farmaceutici S.p.A.

INDUSTRY

NCT02467452 - Non Inferiority of Fixed Combination of Beclomethasone Dipropionate (BDP) + Formoterol Fumarate (FF) + Glycopyrronium Bromide (GB) Versus Combination of Fluticasone Furoate (FlF)/Vilanterol (VI) + Tiotropium Bromide in Chronic Obstructive Pulmonary Disease (COPD) | Biotech Hunter | Biotech Hunter